United Healthcare Approves PoNS Device Reimbursement: What It Means for MS Patients
Millions of Americans rely on United Healthcare for comprehensive insurance coverage. Recent news has brought renewed hope for people with multiple sclerosis (MS): United Healthcare now approves reimbursement for the revolutionary PoNS device. This decision will help more patients access innovative therapy for walking and balance challenges related to MS.
What Is the PoNS Device?
The Portable Neuromodulation Stimulator (PoNS) is an FDA-cleared, non-invasive device. It delivers mild electrical stimulation to the tongue, designed to boost neuroplasticity and promote better balance and gait. Used alongside physical therapy, the device supports adults with mild to moderate MS symptoms, aiding recovery and quality of life for many.
United Healthcare's PoNS Coverage: New Opportunities for MS Patients
With United Healthcare's coverage, members now have significant new options for MS treatment. United Healthcare will reimburse $18,100 for the PoNS device and controller. This sum represents the device's approximate list price, even when obtained out-of-network. According to Multiple Sclerosis News Today, the move follows an earlier agreement by Anthem, making United Healthcare the second major insurer to support this game-changing benefit.
This change is more than administrative—it validates the real-world benefits of the PoNS device. Clinical and at-home studies have shown that consistent use leads to lasting improvements in walking and balance. Those who stick to the treatment protocol often see the greatest gains.
The Impact on Access and Affordability
The device’s coverage through United Healthcare opens the door for more MS patients to seek advanced therapy. Veterans and patients with federal healthcare, like Medicare and Medicaid, also receive partial reimbursements for specific components. However, United Healthcare's approval helps make the therapy far more accessible for the privately insured community.
Helius Medical Technologies, the maker of the PoNS device, stated in their official press release that this reimbursement not only recognizes the device's clinical value but should also lead to more payors considering coverage. Their ongoing strategy is focused on increasing patient access and working with additional insurers.
Financial and Industry Implications
From a broader perspective, Helius Medical Technologies' stock (HSDT) responded positively to the news. As reported by GuruFocus, the reimbursement package matches the device's list price. This alignment sets a strong industry precedent and sends a signal to potential investors and stakeholders about the real-world value of innovative health technologies.
Looking Ahead: What Patients and Providers Should Know
United Healthcare’s approval of the PoNS device for reimbursement means increased confidence in the therapy’s effectiveness and more opportunity for MS patients. As more insurers follow suit, access to breakthrough treatments for chronic conditions like MS is likely to expand.
If you or a loved one are covered by United Healthcare and are exploring treatment options for MS, talk to your healthcare provider about the PoNS device. This new reimbursement decision could unlock meaningful therapy and support on the journey to better mobility and independence.